Videos

What Could IPO and M&A Markets Look Like in the Coming Quarter?

What Could IPO and M&A Markets Look Like in the Coming Quarter?

By Mario Admin | September 6, 2017

What could the acquisition of TearScience and Kala Pharmaceuticals mean for the broader M&A and IPO activity? We ask Andrew Gitkin, managing director and head…

Read More

Cordeiro Explains How DARC May Help Detect Retinal Disease Earlier

By Mario Admin | August 28, 2017

Francesca Cordeiro, MD, PhD, professor, UCL and Imperial College London, Western Eye Hospital London, discusses a promising new technology that could enable much earlier detection…

Read More
Allegro Ophthalmics Reports Phase II Data for Luminate

Allegro Ophthalmics Reports Phase II Data for Luminate

By Mario Admin | August 23, 2017

Vicken Karageozian, MD, president and chief medical officer of Allegro Ophthalmics, reports on Phase II data of lead candidate Luminate as sequential and combination therapy…

Read More
Opthea Limited Updates on Phase I and II OPT-302 Trials

Opthea Updates on Phase I and II OPT-302 Trials

By Mario Admin | August 23, 2017

Opthea CEO & Managing Director Megan Baldwin, PhD, updates the status of Phase I and II dose-escalation studies of the company’s lead agent OPT-302 in…

Read More
Graybug Moves Forward on GB-102 Ascending-Dose Trial

Graybug Moves Forward on GB-102 Ascending-Dose Trial

By Mario Admin | August 23, 2017

CEO Jeff Cleland, PhD, reports the company is moving ahead with trial design for a single ascending-dose study of its candidate GB-102 for intravitreal injection…

Read More
How Did Charles Semba, MD, Find a Home in Ophthalmology?

How Did Charles Semba, MD, Find a Home in Ophthalmology?

By Mario Admin | August 23, 2017

Charles Semba, MD, played integral roles in the development of Lucentis, Xiidra, and more recently Forsight IV’s drug delivery technology. Now the chief medical officer…

Read More
Can REGENXBIO Turn Retina into Anti-VEGF Factory

Can REGENXBIO Turn Retina into Anti-VEGF Factory?

By Mario Admin | August 23, 2017

Stephen Yoo, MD, chief medical officer of REGENXBIO, which utilizes adeno-associated virus to target disease, laid out the company’s plans to run its RGX-314 gene…

Read More
BioTime Examining Possible Retinal Cell Replacements

BioTime Examining Possible Retinal Cell Replacements

By Mario Admin | August 23, 2017

Oscar Cuzzani, MD, PhD, VP of clinical development, detailed the company’s two ophthalmology programs including cell replacement that could be used to treat dry AMD.…

Read More
GenSight Biologics Moving Forward with Clinical Trials

GenSight Biologics Moving Forward with Clinical Trials

By Mario Admin | August 23, 2017

Mohamed Genead, MD, chief medical officer of GenSight Biologics, updated OIS on the early-stage clinical progress of the company’s lead gene therapy product to treat…

Read More
Use of OCT in AMD Clinical Trials

Use of OCT in AMD Clinical Trials

By Mario Admin | August 21, 2017

Andre Witkin, MD, assistant professor, Tufts University School of Medicine, explains how OCT angiography could allow researchers to better visualize neovascular membranes. The images could…

Read More
OCT and OCTA in Diabetic Retinopathy Clinical Trials

Use of OCT and OCTA in Diabetic Retinopathy Clinical Trials

By Mario Admin | August 21, 2017

Amir H. Kashani, MD, PhD, assistant professor of clinical ophthalmology, USC Roski Eye Institute, Keck Medicine of USC, demonstrates how a layered construction of OCT…

Read More
DARC – a New Retinal Imaging Biomarker

Detection of Apoptosing Retinal Cells (DARC) – a New Retinal Imaging Biomarker

By Mario Admin | August 21, 2017

M. Francesca Cordeiro, MD, PhD, professor, UCL and Imperial College London, Western Eye Hospital London, introduces a promising new technology that could enable much earlier…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.